Keywords: Pfizer, Tofacitinib, Ph III, Rheumatoid arthritis, USA, FDA

Positive new data for Pfizer's tofacitinib; possible regulatory delay

Article | 01 August 2012

Print This

Pfizer (NYSE:PFE), the world’s largest drugmaker by sales, yesterday released positive top-line results from ORAL Start ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in